HYBRID EVENT: You can participate in person at Paris, France or Virtually from your home or work.

6th Edition of World Congress on Infectious Diseases

June 24-26, 2024 | Paris, France

June 24 -26, 2024 | Paris, France
Infection 2024

Yousra Abdelmoumen

Speaker at Infection Conferences - Yousra Abdelmoumen
faculty of pharmacy of Casablanca, Morocco
Title : Unraveling the complexity of parvovirus B19 infection: Insights into pathogenesis, Clinical presentations, and therapeutic interventions


Parvovirus B19, a small, single-stranded DNA virus belonging to the Parvoviridae family, has long been recognized as a significant human pathogen. Despite its diminutive size, Parvovirus B19 infection manifests in a spectrum of clinical presentations, ranging from benign childhood exanthems to severe complications in vulnerable populations. This abstract provides a concise yet comprehensive overview of Parvovirus B19 infection, focusing on its pathogenesis, clinical manifestations, diagnostic challenges, and therapeutic strategies.

Parvovirus B19 gains entry into the host through respiratory droplets or blood transfusions, subsequently targeting erythroid progenitor cells in the bone marrow. The virus exploits host cellular machinery for replication, leading to a transient arrest of erythropoiesis and the characteristic erythema infectiosum or "fifth disease" in children. However, in certain individuals, particularly those with underlying hematological disorders or compromised immune systems, Parvovirus B19 infection can result in severe manifestations, including transient aplastic crisis, chronic anemia, and fetal hydrops in pregnant women.

Diagnosing Parvovirus B19 infection poses challenges due to the transient nature of viremia and the limitations of serological assays. Molecular methods, such as polymerase chain reaction (PCR), have emerged as valuable tools for accurate detection and genotyping of Parvovirus B19 strains, facilitating timely diagnosis and appropriate management.

Management of Parvovirus B19 infection primarily involves supportive measures for symptomatic relief. In severe cases, particularly in immunocompromised individuals, intravenous immunoglobulin therapy may be considered to modulate the immune response and inhibit viral replication. Antiviral agents, such as cidofovir and ribavirin, have shown promise in vitro but lack robust clinical evidence to support their routine use.

In conclusion, Parvovirus B19 infection represents a fascinating interplay between a seemingly innocuous virus and the complexities of the human immune system. By elucidating the pathogenesis, clinical manifestations, and therapeutic options for Parvovirus B19 infection, this abstract aims to enhance understanding among clinicians and researchers, ultimately contributing to improved management and outcomes for individuals affected by this viral pathogen.


Yousra Abdelmoumen is a dedicated PhD student specializing in clinical immunology, inflammation, and allergy at the esteemed Medical and Pharmacy Faculty of Casablanca, Morocco. With a keen interest in Parvovirus B19 infection, she delves into its manifestations in both adults and children. Yousra's research sheds light on the varied clinical presentations of Parvovirus B19, from childhood erythema Infectiosum to arthropathy and hematologic disorders in adults.

She participated in numerous oral presentations on Parvovirus B19. Notably at the African Society of Immunodeficiency International Congress in 2023, sparking meaningful discussions among experts.